Acadian Asset Management
INO icon

Acadian Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Acadian Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74,084
Closed -$452K – 1673
2023
Q4 		$452K Buy
74,084
+35,734
+93% +$176K ﹤0.01% 1046
2023
Q3 		$178K Buy
+38,350
New +$212K ﹤0.01% 1213

Other funds holding INO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Acadian Asset Management's INO Position: Q1 2024 in Review

Acadian Asset Management sold out of Inovio Pharmaceuticals (INO) in Q1 2024, closing a stake of 74,084 shares — an estimated $452K sold.

Acadian Asset Management first reported a position in INO in Q3 2023 and held it in 2 quarters. The position peaked at $452K in Q4 2023. 89 funds tracked by Wall St. Rank hold INO as of Q1 2024.

  • Acadian Asset Management reported no remaining Inovio Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 74,084 Inovio Pharmaceuticals shares in Q1 2024, an estimated $452K.
  • Acadian Asset Management first reported a position in Inovio Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Acadian Asset Management's Inovio Pharmaceuticals position peaked at $452K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.